CCM
TEVA icon

Cadence Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Cadence Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-107,511
Closed -$2.62M – 707
2018
Q2 		$2.62M Sell
107,511
-58,252
-35% -$1.19M 0.15% 161
2018
Q1 		$2.83M Buy
+165,763
New +$3.24M 0.18% 124

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Cadence Capital Management's TEVA Position: Q3 2018 in Review

Cadence Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2018, closing a stake of 107,511 shares — an estimated $2.62M sold.

Cadence Capital Management first reported a position in TEVA in Q1 2018 and held it in 2 quarters. The position peaked at $2.83M in Q1 2018. 556 funds tracked by Wall St. Rank hold TEVA as of Q3 2018.

  • Cadence Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Cadence Capital Management sold 107,511 Teva Pharmaceuticals shares in Q3 2018, an estimated $2.62M.
  • Cadence Capital Management first reported a position in Teva Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Cadence Capital Management's Teva Pharmaceuticals position peaked at $2.83M in Q1 2018.
  • 556 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2018.

Based on Cadence Capital Management's 13F filing for Q3 2018, filed 2 Nov 2018.